Putting the Brakes on Breast Cancer: Therapeutic Opportunities to Bring Cancer Stem Cells and the Tumor Microenvironment to a Screeching Halt

Current Drug Targets

Volumn 11, Issue 9, 2010, Pages 1041-1042

  Vargo Gogola, Tracy ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; MICRORNA; NOTCH RECEPTOR; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; SOMATOMEDIN; SONIC HEDGEHOG PROTEIN; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB; WNT PROTEIN;

BREAST CANCER; CANCER STEM CELL; DRUG TARGETING; EDITORIAL; GENE EXPRESSION; HUMAN; METASTASIS; NONHUMAN; TUMOR CELL; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; TUMOR MICROENVIRONMENT;

EID: 78651273171     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945010792006834     Document Type: Editorial

References (15)

1. American Cancer Society. Breast Cancer Facts Fig 2009-2010.
2. Weigelt B, Reis-Filho JS. Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol 2009; 6(12): 718-30.
3. Korkola J, Gray JW. Breast cancer genomes--form and function. Curr Opin Genet Dev 2010; 20(1): 4-14.
4. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100(14): 8418-23.
5. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98(19): 10869-74.
6. Peppercorn J, Perou CM, Carey LA. Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest 2008; 26(1): 1-10.
7. Perez EA, Moreno-Aspitia A, Aubrey TE, Andorfer CA. Adjuvant therapy of triple negative breast cancer. Breast Cancer Res Treat 2010; 120(2): 285-91.
8. Magne N, Chargari C, Conforti R, et al. [Mechanisms of resistance to molecular targeted therapies in breast cancer: update and future]. Bull Cancer 2010; 97(3): 385-95.
9. Wong ST, Goodin S. Overcoming drug resistance in patients with metastatic breast cancer. Pharmacotherapy 2009; 29(8): 954-65.
10. Rivera E. Management of metastatic breast cancer: monotherapy options for patients resistant to anthracyclines and taxanes. Am J Clin Oncol 2010; 33(2): 176-85.
11. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009; 9(9): 631-43.
12. Tkaczuk KH. Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer. Clin Ther 2009; 31 Pt 2: 2273-89.
13. Brufsky A. Trastuzumab-based therapy for patients with HER2-positive breast cancer: from early scientific development to foundation of care. Am J Clin Oncol 2010; 33(2): 186-95.
14. Morrow PK, Zambrana F, Esteva FJ. Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer. Breast Cancer Res 2009; 11(4): 207.
15. Harichand-Herdt S, Zelnak A, O'Regan R. Endocrine therapy for the treatment of postmenopausal women with breast cancer. Expert Rev Anticancer Ther 2009; 9(2): 187-98.